<DOC>
	<DOCNO>NCT00165633</DOCNO>
	<brief_summary>The purpose study determine superiority inhibitory effect safety Menatetrenone ( E0167 ) recurrence patient hepatocellular carcinoma .</brief_summary>
	<brief_title>A Phase II/III Clinical Study Inhibitory Effects E0167 Recurrence Hepatocellular Carcinoma</brief_title>
	<detailed_description>The study conduct multicenter , randomize , parallel , placebo-controlled , double-blind comparative clinical study . Patients randomly assign double-blind manner receive 45 90 mg/day oral vitamin K2 identical-appearing placebo . Study drug administer orally three time daily meal recurrence .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Menatetrenone</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<criteria>1 . 20 year old time obtain consent . 2 . Systemic condition 0 2 score Performance Status ( accord Eastern Cooperative Oncology Group : ECOG ) . 3 . Diagnosis hepatocellular carcinoma base follow 1 ) 2 ) . 1 ) Patients confirm early tumor stain typical finding ( ) hepatocellular carcinoma CT MRI image 2 ) Patients underwent tumor biopsy histopathologically diagnose hepatocellular carcinoma 4 . Primary onset recurrence hepatocellular carcinoma 1 time . 5 . Patients underwent follow 1 ) 2 ) within 90 day prior registration determine therapeutic effect . 1 ) Patients underwent local therapy achieve complete hepatonecrosis confirm complete hepatonecrosis CT image MRI . 2 ) Patients underwent surgical treatment ( ) confirm residual tumor CT MRI image . 6 . Patients meet following item determine liver function : 1 ) Albumin 2.8 g/dL 2 ) Total bilirubin 2.0 mg/dL 3 ) Prothrombin activation 40 % 7 . Patients give full explanation study participation ( include cancer notification ) submit write consent form understand well voluntary study . 1 . Hepatocellular carcinoma : 1 ) Patients extrahepatic metastasis 2 ) Patients portal invasion 3 ) Patients experience systemic administration antimalignant tumor drug treat hepatocellular carcinoma 4 ) Patients treated transcatheter arterial chemoembolization ( TAE ) alone nonlocal therapy hepatocellular carcinoma 2 . Hepatitis : 1 ) Patients ( ) ( b ) previously treat interferon preparation ( include clinical study ) . ( ) Patients chronic hepatitis C virus ( HCV ) show HCVRNA negative ( b ) Patients viral hepatitis treat interferon preparation within last 2 year ( day , 6 month earlier day obtain consent form ) ( c ) Patients encephalopathy pharmacotherapy ineffective ( ) Patients ascites pleural effusion manage diuretic 3 . Systemic condition : 1 ) Patients unable receive oral administration 2 ) Patients history gastrectomy extensive resection digestive tract 3 ) Patients suspect biliary occlusion , choleretic disorder , cholecystectomy , malabsorption liposoluble agent 4 ) Patients complicate serious disease cardiovascular ( e.g. , myocardial infarction ) , hematological ( e.g. , aplastic anemia ) , and/or renal dysfunction ( e.g. , acute chronic renal failure ) 5 ) Patients multiple cancer ( within 5year cancerfree period [ day 5 year earlier day obtain consent form ] ) 4 . Drug administration : 1 ) Patients warfarin potassium therapy 2 ) Patients known history drug allergy E0167 ingredients 3 ) Patients receive vitamin K preparation within recent 6 month ( day 6 month earlier day obtain consent form ) 5 . Other exclusion criterion 1 ) Women pregnant , lactating , childbearing potential , intention become pregnant 2 ) Patients presently participate another clinical study ( except followup survey study outcome ) 3 ) Patients judge ineligible study entry investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Hepatocellular</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>recurrence</keyword>
	<keyword>Vitamin K2</keyword>
	<keyword>E0167</keyword>
</DOC>